Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2002 • ACR Convergence 2022
Do SMS and Email Reminders Increase the Rate of Seasonal Influenza Vaccination in RA Patients Treated with Biologics: A Nested Randomized Controlled Trial Within the ART Registry?
Raphaèle Seror¹, Gabriel Baron², Sylvie Miconnet³, Rakiba Belkhir³, Martin Soubrier⁴, pascale thevenot⁵, andre basch⁶, Marie Truchetet⁷, Pascal Claudepierre⁸, Emmanuelle Dernis⁹, Hubert Marotte¹⁰, René-Marc Flipo¹¹, Olivier Brocq¹², Jacques Morel¹³, CARINE SALLIOT¹⁴, Bruno Fautrel¹⁵, Alain Saraux¹⁶, CHARLES LESKE¹⁷, Naïma Hamamouche¹⁸, Thierry schaeverbeke¹⁹, Xavier Mariette²⁰, Adeline Ruyssen-Witrand²¹ and Philippe Ravaud²², ¹University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ²AP-HP Hôtel Dieu Hospital, Université Paris Descartes, Paris, France, ³Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ⁴Gabriel-Montpied Hospital, Clermont-Ferrand, France, ⁵French Society of rheumatology, Paris, France, ⁶Infirmerie Protestante de Lyon, Caluire-et-Cuire, France, ⁷Bordeaux University Hospital, Bordeaux, France, ⁸Paris Est Creteil University, Creteil, France, ⁹LE MANS general hospital, LE MANS, France, ¹⁰INSERM 1059, Saint-Etienne, France, ¹¹CHU Lille, Boulogne-Billancourt, France, ¹²Rheumatology- CH Princesse Grace, Monaco, Monaco, ¹³University and CHU Montpellier, Montpellier, France, ¹⁴CHR orleans, Orleans, France, ¹⁵Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ¹⁶CHU Brest, Brest, France, ¹⁷Hospital, Cholet, France, ¹⁸e-health Services Sanoïa, Gémenos, France, ¹⁹CHU de Bordeaux, Bordeaux, France, ²⁰Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²¹CHU de Toulouse, Toulouse, France, ²²Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: In patients treated with biologics, vaccination against influenza is recommended. However, vaccination coverage remains very low. The use of automatic digital reminders is an…
Abstract Number: 2179 • ACR Convergence 2022
Spatial and Single-Cell Transcriptomics Identify Alcam+ Macrophage / CD6+ T-Cell Interactions and Accumulation of IgG2b+ Class-Switched Plasma Cells in Marco+ Medullary Sinuses of Joint-Draining Popliteal Lymph Nodes in TNF-Tg Mice with Advanced Arthritis
H. Mark Kenney¹, Yue Peng², Kiana Chen², Javier Rangel-Moreno², Elizabeth Pritchett², Jeffrey Fox², Benjamin Korman³, Jennifer Anolik², Lianping Xing⁴, Christopher Ritchlin⁵, Edward Schwarz² and Chia-Lung Wu², ¹University of Rochester Medical Center, Henrietta, NY, ²University of Rochester Medical Center, Rochester, NY, ³University of Rochester, Rochester, NY, ⁴University of Rochester Medical Center, Webster, NY, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Severe inflammatory-erosive arthritis in tumor necrosis factor transgenic (TNF-Tg) mice is associated with B-cell translocation into sinuses of joint-draining popliteal lymph nodes (PLNs) via…
Abstract Number: 2234 • ACR Convergence 2022
Obesity, Adipokines, and Chronic and Persistent Pain in Rheumatoid Arthritis
Joshua Baker¹, Kristin Wipfler², Marianna Olave³, Sofia Pedro⁴, Patricia Katz⁵ and Kaleb Michaud⁶, ¹University of Pennsylvania, Philadelphia, PA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁴Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁵UCSF, San Rafael, CA, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Obesity has been linked to chronic pain and pain sensitization in the general population and among patients with rheumatoid arthritis (RA). The mechanism by…
Abstract Number: 0051 • ACR Convergence 2022
Identification of a Transcription Factor That Drives Polarization Toward Tissue-destructive Fibroblasts in Arthritis
MINGLU YAN¹, Noriko Komatsu¹, Ryunosuke Muro¹, Hiroyuki Takaba¹, Takeshi Nitta¹, Kazuo Okamoto¹, Masayuki Tsukasaki² and Hiroshi Takayanagi¹, ¹University of Tokyo, Tokyo, Japan, ²The Univerisity of Tokyo, Tokyo, Japan
Background/Purpose: Fibroblasts exert important homeostatic functions but can also drive disease pathogenesis. In rheumatoid arthritis (RA), synovial fibroblasts (SFs) contribute to the joint destruction by…
Abstract Number: 0096 • ACR Convergence 2022
Delayed Referral of Female Rheumatoid Arthritis Patients: Where Are We Now? A Study Spanning Three Decades
Bastiaan van Dijk¹ and Annette van der Helm-van Mil², ¹Leiden University Medical Centre (LUMC), Leiden, Netherlands, ²Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Delayed referral of female RA-patients was reported twenty years ago: the time between the first appointment with the general practitioner (GP) and referral to…
Abstract Number: 0210 • ACR Convergence 2022
Themes in Patients’ Discordance with Provider’s Rheumatoid Arthritis Treatment Goals Relate to Patient Age, Gender, and Ethnicity
Kelly O'Neill¹, Pamela Sinicrope², Cynthia Crowson³, Kathryne Marks⁴, Rachel Giblon⁵, Elena Myasoedova² and John Davis², ¹Rheumatoid Patient Foundation, Winter Springs, FL, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: We previously reported on themes in patients' treatment goals and their association with rheumatoid arthritis (RA) disease activity (DA) and aspects of rheumatology care,…
Abstract Number: 0255 • ACR Convergence 2022
Is Abatacept as Effective and Safe in Rheumatoid Arthritis Patients with Previous Malignancy as in Those Without?
Yosuke Kunishita¹, Kayo Harita², Chikara Honda², Masaki Mitsuhasi² and Shouhei Nagaoka², ¹Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Kanagawa, Japan, ²Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan
Background/Purpose: In 2019, a study based on post-marketing surveillance data in Japan reported that abatacept (ABT) was as effective and safe in elderly patients with…
Abstract Number: 0271 • ACR Convergence 2022
Temporal Trends and Risk of Rheumatoid Arthritis in Celiac Disease Patients: A Nationwide Population-based Study
Brinda Basida¹, maryam haider¹, Noren Din² and Vinit Gilvaz³, ¹DMC/Sinai Grace Hospital, Detroit, MI, ²DMC/Sinai- Grace Hospital, Birmingham, AL, ³Brown University, East Providence, RI
Background/Purpose: There has been an increasing global prevalence of celiac diseases (CD) and rheumatoid arthritis (RA). Modifications in proteins play a significant role in the…
Abstract Number: 0289 • ACR Convergence 2022
Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry
Song-Chou Hsieh¹, Wei-Sheng Chen², Jui-Chieh Hu³, Wan-Yu Sung⁴, Wen-Chan Tsai⁴, Hsiang-Cheng Chen⁵, Chung-Ming Huang⁶, Edward Kuo⁷, James Wee⁸, John Woolcott⁹ and Yi-Hsing Chen¹⁰, ¹Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ²Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ³Division of Allergy, Immunology and Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁴Department of Allergy, Immunology, and Rheumatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ⁵Division of Immunology, Rheumatology, and Allergy, Department of Medicine, Tri-Service General Hospital, Taipei, Taiwan, ⁶Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, ⁷Pfizer Ltd, Taipei, Taiwan, ⁸Pfizer Inc, Makati City, Philippines, ⁹Pfizer, Inc, Collegeville, PA, ¹⁰Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA and was approved under Taiwan's National Health Insurance (NHI) reimbursement system in…
Abstract Number: 0306 • ACR Convergence 2022
Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Gabriela Schmajuk¹, Nevin Hammam², Jing Li³, David Collier⁴, Greg Kricorian⁵ and Scott Stryker⁶, ¹UCSF / SFVA, San Francisco, CA, ²Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Amgen Inc., Simi Valley, CA, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Amgen Inc., San Francisco, CA
Background/Purpose: Data regarding the maintenance of disease activity (DA) and treatment persistence in patients (pts) who switched from combination therapy to monotherapy for the management…
Abstract Number: 0511 • ACR Convergence 2022
SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy
Nedal Darwish¹, Sameer Jhaveri², Uma Yoganathan¹, Halima Bakillah¹, Kelly Y. Chun³, Thomas Wasser⁴ and James Freeman¹, ¹Arnot Ogden Medical Center, Elmira, NY, ²Lake Erie College of Osteopathic Medicine, Elmira, NY, ³Labcorp, Calabasas, CA, ⁴Consult-Stat, Macungie, PA
Background/Purpose: Patients with chronic inflammatory arthritis (CIA) are at increased risk for the development and mortality from COVID-19. Vaccinations are integral to the management of…
Abstract Number: 0582 • ACR Convergence 2022
Development of Novel Glucocorticoid as Immunology Antibody-Drug Conjugate Payload for the Treatment of Autoimmune and Inflammatory Diseases
Xiaojuan Chai¹, Yayuan Fu¹, Lifeng Liu¹, Yuxi Yan¹, Quan Zhao¹, Xiaoqing Liu², Yixin Zou¹, Jing Dai¹, Feng Tang¹, Zhuoxiao Cao¹ and Renhong Tang¹, ¹Simcere Pharmaceutical Group, Shanghai, China, ²Simcere Pharmaceutical Group, Nanjing, China
Background/Purpose: Glucocorticoids (GCs) are widely used to treat a variety of autoimmune and inflammatory diseases like rheumatoid arthritis, inflammatory bowel disease, and asthma. The anti-inflammatory…
Abstract Number: 0603 • ACR Convergence 2022
Survivin-dependent Regulation of Bivalent Chromatin and Its Relevance for Adaptive Immunity
Venkataragavan Chandrasekaran¹, Nina Oparina², Karin Andersson², Malin Erlandsson², Maria-Jose Garcia-Bonete³, Maja Jensen⁴, Gergely Katona⁵ and Maria Bokarewa⁶, ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ³Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden, ⁴Department of Chemistry and Molecular Biology, Gothenburg, Sweden, ⁵Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: Bivalent chromatin (BvCR) is characterized by simultaneous binding of active and repressive modifications to the histone H3 proteins. Influencing expression of the genes, BvCR…
Abstract Number: 0621 • ACR Convergence 2022
Altered Immunological Circadian Rhythms and the Effect of Treatment with Glucocorticoids on Circadian Rhythms of Immune Cells in Patients with Rheumatoid Arthritis: Bring Back the Rhythm
Siska Wilantri¹, Cindy Strehl¹, Dimas Abdirama¹, Timo Gaber¹, Robert Biesen² and Frank Buttgereit¹, ¹Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
Background/Purpose: Clinical symptoms of rheumatoid arthritis (RA), including pain, joint stiffness, and swelling, exhibit a distinct circadian rhythm that exacerbates in the early morning in…
Abstract Number: 0731 • ACR Convergence 2022
Remote Monitoring of Chronic Inflammatory Musculoskeletal Diseases– Results of the Digireuma Feasibility Study
Diego Benavent¹, Luis Fernández-Luque², María Sanz-Jardón¹, Victoria Navarro-Compán³, Pau Altur², Enrique Calvo⁴, Leticia Lojo⁴, Alejandro Balsa⁵ and Chamaida Plasencia-Rodriguez⁶, ¹La Paz University Hospital, Madrid, Spain, ²AdheraHealth Inc, Palo Alto, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Hospital Universitario Infanta Leonor, Madrid, Spain, ⁵Hospital La Paz Institute for Health Research, Madrid, Spain, ⁶Rheumatology Department, La Paz University Hospital, Madrid, Spain
Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMDs) require a tailored follow-up that is limited by the capacity of healthcare professionals. The implementation of innovative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.